Telomere Length Influences Cancer Cell Differentiation In Vivo

Molecular and Cellular Biology

Volumn 33, Issue 15, 2013, Pages 2988-2995

  Hirashima, Kyotaro ^a   Migita, Toshiro ^a,b   Sato, Shigeo ^a   Muramatsu, Yukiko ^a   Ishikawa, Yuichi ^c   Seimiya, Hiroyuki ^a  

^a CANCER CHEMOTHERAPY CENTER   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c CANCER INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

NERVE CELL ADHESION MOLECULE; TELOMERASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER PROGNOSIS; CARCINOGENESIS; CELL AGING; CELL DIFFERENTIATION; CELL ELONGATION; CONTROLLED STUDY; CYTOCHEMISTRY; ENZYME ACTIVITY; GENE EXPRESSION PROFILING; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INNATE IMMUNITY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RADIOIMMUNOPRECIPITATION; SOUTHERN BLOTTING; TELOMERE HOMEOSTASIS; UPREGULATION; WESTERN BLOTTING;

ANIMALS; CELL DIFFERENTIATION; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PROSTATE; PROSTATIC NEOPLASMS; TELOMERASE; TELOMERE; UP-REGULATION;

EID: 84880688651     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00136-13     Document Type: Article

References (35)

1. Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. Cell 100:57-70.
2. Niida H, Matsumoto T, Satoh H, Shiwa M, Tokutake Y, Furuichi Y, Shinkai Y. 1998. Severe growth defect in mouse cells lacking the telomerase RNA component. Nat. Genet. 19:203-206.
3. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW. 1994. Specific association of human telomerase activity with immortal cells and cancer. Science 266:2011-2015.
4. Maser RS, DePinho RA. 2002. Connecting chromosomes, crisis, and cancer. Science 297:565-569.
5. Meeker AK, Hicks JL, Platz EA, March GE, Bennett CJ, Delannoy MJ, De Marzo AM. 2002. Telomere shortening is an early somatic DNA alteration in human prostate tumourigenesis. Cancer Res. 62:6405-6409.
6. Sommerfeld HJ, Meeker AK, Piatyszek MA, Bova GS, Shay JW, Coffey DS. 1996. Telomerase activity: a prevalent marker of malignant human prostate tissue. Cancer Res. 56:218-222.
7. de Lange T. 2005. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev. 19:2100-2110.
8. Marcand S, Gilson E, Shore D. 1997. A protein-counting mechanism for telomere length regulation in yeast. Science 275:986-990.
9. Greenberg RA, Chin L, Femino A, Lee KH, Gottlieb GJ, Singer RH, Greider CW, DePinho RA. 1999. Short dysfunctional telomeres impair tumourigenesis in the INK4a(delta2/3) cancer-prone mouse. Cell 97:515-525.
10. González-Suárez E, Samper E, Flores JM, Blasco MA. 2000. Telomerasedeficient mice with short telomeres are resistant to skin tumourigenesis. Nat. Genet. 26:114-117.
11. Feldser DM, Greider CW. 2007. Short telomeres limit tumour progression in vivo by inducing senescence. Cancer Cell 11:461-469.
12. Taboski MA, Sealey DC, Dorrens J, Tayade C, Betts DH, Harrington L. 2012. Long telomeres bypass the requirement for telomere maintenance in human tumourigenesis. Cell Rep. 1:91-98.
13. Chin L, Artandi SE, Shen Q, Tam A, Lee SL, Gottlieb GJ, Greider CW, DePinho RA. 1999. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 97:527-538.
14. Baur JA, Zou Y, Shay JW, Wright WE. 2001. Telomere position effect in human cells. Science 292:2075-2077.
15. Seimiya H, Muramatsu Y, Ohishi T, Tsuruo T. 2005. Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics. Cancer Cell 7:25-37.
16. Tanaka M, Kagawa H, Yamanashi Y, Sata T, Kawaguchi Y. 2003. Construction of an excisable bacterial artificial chromosome containing a full-length infectious clone of herpes simplex virus type 1: viruses reconstituted from the clone exhibit wild-type properties in vitro and in vivo construction of an excisable bac. J. Virol. 77:1382-1391.
17. Meeker AK, Gage WR, Hicks JL, Simon I, Coffman JR, Platz EA, March GE, De Marzo AM. 2002. Telomere length assessment in human archival tissues: combined telomere fluorescence in situ hybridization and immunostaining. Am. J. Pathol. 160:1259-1268.
18. Cookson JC, Dai F, Smith V, Heald RA, Laughton CA, Stevens MF, Burger AM. 2005. Pharmacodynamics of the G-quadruplex-stabilizing in human tumour cells correlates with telomere length and can be enhanced, or antagonized, with cytotoxic agents. Mol. Pharmacol. 68:1551-1558.
19. Nugent CI, Lundblad V. 1998. The telomerase reverse transcriptase: components and regulation. Genes Dev. 12:1073-1085.
20. Choi J, Southworth LK, Sarin KY, Venteicher AS, Ma W, Chang W, Cheung P, Jun S, Artandi MK, Shah N, Kim SK, Artandi SE. 2008. TERT promotes epithelial proliferation through transcriptional control of a Myc- and Wnt-related developmental program. PLoS Genet. 4:e10. doi:10.1371/journal.pgen.0040010.
21. Maida Y, Yasukawa M, Furuuchi M, Lassmann T, Possemato R, Okamoto N, Kasim V, Hayashizaki Y, Hahn WC, Masutomi K. 2009. AnRNA-dependent RNA polymerase formed by TERT and the RMRP RNA. Nature 461:230-235.
22. Kim M, Xu L, Blackburn EH. 2003. Catalytically active human telomerase mutants with allele-specific biological properties. Exp. Cell Res. 288:277-287.
23. Nagy A. 2000. Cre recombinase: the universal reagent for genome tailoring. Genesis 26:99-109.
24. Derycke LD, Bracke ME. 2004. N-cadherin in the spotlight of cell-cell adhesion, differentiation, embryogenesis, invasion and signalling. Int. J. Dev. Biol. 48:463-476.
25. Tanaka H, Kono E, Tran CP, Miyazaki H, Yamashiro J, Shimomura T, Fazli L, Wada R, Huang J, Vessella RL, An J, Horvath S, Gleave M, Rettig MB, Wainberg ZA, Reiter RE. 2010. Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat. Med. 16:1414-1420.
26. Duarte CW, Willey CD, Zhi D, Cui X, Harris JJ, Vaughan LK, Mehta T, McCubrey RO, Khodarev NN, Weichselbaum RR, Gillespie GY. 2012. Expression signature of IFN/STAT1 signaling genes predicts poor survival outcome in glioblastoma multiforme in a subtype-specific manner. PLoS One 7:e29653. doi:10.1371/journal.pone.0029653.
27. Kim S, Koga T, Isobe M, Kern BE, Yokochi T, Chin YE, Karsenty G, Taniguchi T, Takayanagi H. Stat1 functions as a cytoplasmic attenuator of Runx2 in the transcriptional program of osteoblast differentiation. Gene Dev. 3:1979-1991.
28. Cui K, Zang C, Roh TY, Schones DE, Childs RW, Peng W, Zhao K. 2009. Chromatin signatures in multipotent human hematopoietic stem cells indicate the fate of bivalent genes during differentiation. Cell Stem Cell 4:80-93.
29. Martinez P, Thanasoula M, Carlos AR, Go'mez-Lo'pez G, Tejera AM, Schoeftner S, Dominguez O, Pisano DG, Tarsounas M, Blasco MA. 2010. Mammalian Rap1 controls telomere function and gene expression through binding to telomeric and extratelomeric sites. Nat. Cell Biol. 12:768-780.
30. Simonet T, Zaragosi LE, Philippe C, Lebrigand K, Schouteden C, Augereau A, Bauwens S, Ye J, Santagostino M, Giulotto E, Magdinier F, Horard B, Barbry P, Waldmann R, Gilson E. 2011. The human TTAGGG repeat factors 1 and 2 bind to a subset of interstitial telomeric sequences and satellite repeats. Cell Res. 21:1028-1038.
31. Coppé JP, Patil CK, Rodier F, Sun Y, Muñoz DP, Goldstein J, Nelson PS, Desprez PY, Campisi J. 2008. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumour suppressor. PLoS Biol. 6:2853-2868.
32. Lou Z, Wei J, Riethman H, Baur JA, Voglauer R, Shay JW, Wright WE. 2009. Telomere length regulates ISG15 expression in human cells. Aging 1:608-621.
33. Andersen JB, Hassel BA. 2006. The interferon regulated ubiquitin-like protein, ISG15, in tumourigenesis: friend or foe? Cytokine Growth Factor Rev. 17:411-421.
34. Satake H, Tamura K, Furihata M, Anchi T, Sakoda H, Kawada C, Iiyama T, Ashida S, Shuin T. 2010. The ubiquitin-like molecule interferon-stimulated gene 15 is overexpressed in human prostate cancer. Onc. Rep. 23:11-16.
35. Arnoult N, Van Beneden A, Decottignies A. 2012. Telomere length regulates TERRA levels through increased trimethylation of telomeric H3K9 and HP1. Nat. Struct. Mol. Biol. 19:948-956.